Patents by Inventor William W. Turner, Jr.

William W. Turner, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11814376
    Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.
    Type: Grant
    Filed: January 4, 2021
    Date of Patent: November 14, 2023
    Assignees: Assembly Biosciences, Inc., Indiana University Research and Technology Corporation
    Inventors: William W. Turner, Jr., Lee D. Arnold, Hans Maag, Leping Li, Mark G. Bures, Simon Nicolas Haydar, Samson Francis
  • Publication number: 20230044112
    Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.
    Type: Application
    Filed: January 4, 2021
    Publication date: February 9, 2023
    Applicants: Assembly Biosciences, Inc., INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
    Inventors: William W. Turner, JR., Lee D. Arnold, Hans Maag, Leping Li, Mark G. Bures, Simon Nicolas Haydar, Samson Francis
  • Publication number: 20230019129
    Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.
    Type: Application
    Filed: January 21, 2021
    Publication date: January 19, 2023
    Applicants: Indiana University Research and Technology Corporation, Assembly Biosciences, Inc.
    Inventors: William W. Turner, JR., Lee Daniel Arnold, Hans Maag, Adam Zlotnick
  • Patent number: 11078170
    Abstract: The present disclosure provides, in part, cyclic sulfamide compounds, and pharmaceutical compositions thereof, useful as modulators of Hepatitis B (HBV) core protein, and methods of treating Hepatitis B (HBV) infection.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: August 3, 2021
    Assignee: Assembly Biosciences, Inc.
    Inventors: William W. Turner, Jr., Leping Li, Simon Nicolas Haydar, Mark G. Bures, Roopa Rai, Samson Francis, Lee D. Arnold
  • Patent number: 10987360
    Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: April 27, 2021
    Assignee: Assembly Biosciences, Inc.
    Inventors: William W. Turner, Jr., Lee D. Arnold, Leping Li, Mark G. Bures, Simon Nicolas Haydar, Hans Maag, Lynne Bannen
  • Patent number: 10968211
    Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.
    Type: Grant
    Filed: May 30, 2019
    Date of Patent: April 6, 2021
    Assignees: Assembly Biosciences, Inc., INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
    Inventors: William W. Turner, Jr., Lee D. Arnold, Hans Maag, Leping Li, Mark G. Bures, Simon Nicolas Haydar, Samson Francis
  • Patent number: 10947224
    Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: March 16, 2021
    Assignees: Indiana University Research and Technology Corporation, Assembly Biosciences, Inc.
    Inventors: William W. Turner, Jr., Lee Daniel Arnold, Hans Maag, Adam Zlotnick
  • Publication number: 20200157070
    Abstract: The present disclosure provides, in part, cyclic sulfamide compounds, and pharmaceutical compositions thereof, useful as modulators of Hepatitis B (HBV) core protein, and methods of treating Hepatitis B (HBV) infection.
    Type: Application
    Filed: March 1, 2018
    Publication date: May 21, 2020
    Inventors: William W. Turner, JR., Leping Li, Simon Nicolas Haydar, Mark G. Bures, Roopa Rai, Samson Francis, Lee D. Arnold
  • Publication number: 20200131168
    Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.
    Type: Application
    Filed: May 30, 2019
    Publication date: April 30, 2020
    Inventors: William W. Turner, JR., Lee D. Arnold, Hans Maag, Leping Li, Mark G. Bures, Simon Nicolas Haydar, Samson Francis
  • Publication number: 20190255067
    Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp.
    Type: Application
    Filed: September 14, 2017
    Publication date: August 22, 2019
    Inventors: William W. Turner, JR., Lee D. Arnold, Leping Li, Mark G. Bures, Simon Nicolas Haydar, Hans Maag, Lynne Bannen
  • Patent number: 10273228
    Abstract: Novel assembly effector compounds having a therapeutic effect against hepatitis B viral (HBV) infection are disclosed. Assembly effector molecules described herein can lead to defective viral assembly and also may affect other viral activities associated with chronic HBV infection. Also disclosed is a process to synthesize disclosed compounds, method of treatment of HBV by administration of disclosed compounds, and use of these compounds in the manufacture of medicaments against HBV.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: April 30, 2019
    Assignees: Indiana University Research and Technology Corporation, Assembly Biosciences, Inc.
    Inventors: Lee Daniel Arnold, Hans Maag, William W. Turner, Jr.
  • Patent number: 10220034
    Abstract: Novel assembly effector compounds having a therapeutic effect against hepatitis B viral (HBV) infection are disclosed. Assembly effector molecules described herein can lead to defective viral assembly and also may affect other viral activities associated with chronic HBV infection. Also disclosed is a process to synthesize disclosed compounds, method of treatment of HBV by administration of disclosed compounds, and use of these compounds in the manufacture of medicaments against HBV.
    Type: Grant
    Filed: October 16, 2014
    Date of Patent: March 5, 2019
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Adam Zlotnick, Lichun Li, William W. Turner, Jr., Samson Francis
  • Patent number: 10183936
    Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: January 22, 2019
    Assignees: Indiana University Research and Technology Corporation, Assembly Biosciences, Inc.
    Inventors: William W. Turner, Jr., Lee Daniel Arnold, Hans Maag, Adam Zlotnick
  • Publication number: 20180273521
    Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.
    Type: Application
    Filed: April 27, 2018
    Publication date: September 27, 2018
    Applicants: Indiana University Research and Technology Corporationt, Assembly Biosciences, Inc.
    Inventors: William W. Turner, JR., Lee Daniel Arnold, Hans Maag, Adam Zlotnick
  • Publication number: 20180099952
    Abstract: Novel assembly effector compounds having a therapeutic effect against hepatitis B viral (HBV) infection are disclosed. Assembly effector molecules described herein can lead to defective viral assembly and also may affect other viral activities associated with chronic HBV infection. Also disclosed is a process to synthesize disclosed compounds, method of treatment of HBV by administration of disclosed compounds, and use of these compounds in the manufacture of medicaments against HBV.
    Type: Application
    Filed: April 15, 2016
    Publication date: April 12, 2018
    Applicants: Indiana University Research and Technology Corporation, Assembly Biosciences, Inc.
    Inventors: Lee Daniel Arnold, Hans Maag, William W. Turner, Jr.
  • Patent number: 9796722
    Abstract: Novel virus assembly effector compounds having a therapeutic effect against Hepatitis B viral infection are disclosed. Assembly effector molecules described herein can lead to defective viral assembly and also may affect other viral activities associated with chronic HBV infection. Also disclosed are pharmaceutical compositions including the disclosed compounds, methods of treatment of HBV infection, and a process to synthesize the disclosed compounds.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: October 24, 2017
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Adam Zlotnick, Lichun Li, William W. Turner, Jr.
  • Publication number: 20170015658
    Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.
    Type: Application
    Filed: March 13, 2015
    Publication date: January 19, 2017
    Inventors: William W. Turner, JR., Lee Daniel Arnold, Hans Maag, Adam Zlotnick
  • Publication number: 20160271130
    Abstract: Novel assembly effector compounds having a therapeutic effect against hepatitis B viral (HBV) infection are disclosed. Assembly effector molecules described herein can lead to defective viral assembly and also may affect other viral activities associated with chronic HBV infection. Also disclosed is a process to synthesize disclosed compounds, method of treatment of HBV by administration of disclosed compounds, and use of these compounds in the manufacture of medicaments against HBV.
    Type: Application
    Filed: October 16, 2014
    Publication date: September 22, 2016
    Applicant: Indiana University Research and Technology Corp.
    Inventors: Adam Zlotnick, Lichun Li, William W. Turner, Jr., Samson Francis
  • Patent number: 6916784
    Abstract: Provided are compounds of the formula (1): wherein R? is hydrogen, methyl or NH2C(O)CH2—; R? and R?? are independently methyl or hydrogen; R adn Ry are independently hydroxy or hydrogen; R1 is hydroxy, hydrogen, or hydroxysulfonyloxy; R7 is hydroxy, hydrogen, hydroxysulfonyloxy or phosphonooxy; R2 is a novel acyl side chain. Also provided are novel formulations, methods of inhibiting fungal and parasitic activity, and a process for preparing dideoxy (R?H) forms of the compounds.
    Type: Grant
    Filed: February 27, 2003
    Date of Patent: July 12, 2005
    Assignee: Eli Lilly and Company
    Inventors: Frederick J. Burkhardt, Manuel Debono, Jeffrey S. Nissen, William W. Turner, Jr.
  • Patent number: 6743777
    Abstract: Provided are compounds of the formula (1): wherein R′ is hydrogen, methyl or NH2C(O)CH2—; R″ and R′″ are independently methyl or hydrogen; R adn Ry are independently hydroxy or hydrogen; R1 is hydroxy, hydrogen, or hydroxysulfonyloxy; R7 is hydroxy, hydrogen, hydroxysulfonyloxy or phosphonooxy; R2 is a novel acyl side chain. Also provided are novel formulations, methods of inhibiting fungal and parasitic activity, and a process for preparing dideoxy (R=H) forms of the compounds.
    Type: Grant
    Filed: February 27, 2002
    Date of Patent: June 1, 2004
    Assignee: Eli Lilly and Company
    Inventors: Frederick J. Burkhardt, Manuel Debono, Jeffrey S. Nissen, William W. Turner, Jr.